ArticleCureus2025
Whole-Body Diffusion-Weighted Imaging With Background Body Signal Suppression for Primary Tumor Detection in Patients With Brain Metastases.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) is a magnetic resonance imaging (MRI) technique that enables noninvasive, radiation-free whole-body screening. By emphasizing diffusion-restricted regions while suppressing background signals, DWIBS has emerged as a potential alternative or complement to fludeoxyglucose-18 positron emission tomography (FDG-PET), particularly for the detection of primary tumors and metastases. Herein, we report two cases in which DWIBS highlighted suspicious lesions that guided targeted CT and biopsy, leading to the identification of the primary tumor after intracerebral metastasis. The first case involved a man in his 60s who presented with headache and diplopia. Brain MRI revealed clival metastasis, which was diagnosed as squamous cell carcinoma. DWIBS highlighted a focal lesion in the mid-esophagus, which prompted targeted contrast-enhanced CT and subsequent endoscopic biopsy that confirmed esophageal squamous cell carcinoma as the primary site. DWIBS revealed a suspicious lesion in the esophagus, which was later confirmed as an esophageal carcinoma. In the second case, a man in his 50s presented with hemiparesis due to brain metastasis, which was diagnosed as adenocarcinoma. Initial computed tomography and FDG-PET/CT did not localize the primary site; DWIBS subsequently demonstrated a focal diffusion-restricted lesion in the right lung apex, which directed further evaluation and was ultimately consistent with a lung primary. While the initial computed tomography and FDG-PET failed to identify the primary site, DWIBS later detected a lesion in the right lung apex, consistent with lung cancer. These cases illustrate the ability of DWIBS to provide actionable complementary information when FDG-PET is unavailable or yields negative findings. DWIBS, which is accessible, cost-effective, and does not involve radiation exposure, represents a promising imaging modality for oncological practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.